EVALUATION OF SPINAL CORD WHITE MATTER INJURY USING DTI

使用 DTI 评估脊髓白质损伤

基本信息

  • 批准号:
    8472543
  • 负责人:
  • 金额:
    $ 39.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diffusion tensor imaging (DTI) measures the diffusion of water molecules, which reflects the microstructural organization of the tissues of interest. Previously, we have demonstrated that water diffusion parallel to the fibers, axial diffusivity, is much greater than that perpendicular to the fibers, radial diffusivity. We further demonstrated that demyelination leads to an increase in radial diffusivity and axonal damage leads to a decrease in axial diffusivity in mouse models of white matter injuries. In this proposal, we hypothesized that the in vivo DTI biomarker of axonal injury, i.e., decreased axial diffusivity, may serve as an early and accurate surrogate endpoint for outcome prediction in spinal cord injury (SCI). Axonal damage occurring in the acute period following SCI is the primary cause of long-term neurological disabilities in SCI. Thus, the primary goal of the proposed study is to determine at what post-injury time points can DTI be used to accurately predict functional (behavioral and electrophysiological) outcomes in rodent models of SCI. A translation of the use of DTI biomarker of axonal injury to cervical spondylotic myelopathy (CSM) patients will also be pursued to test the efficacy of this marker in the clinical setting. Three key questions are asked: (1) Does the in vivo DTI axonal injury biomarker reflect the underlying structural changes and predict long-term neurological outcome in SCI mice? (2) Do the in vivo DTI biomarkers correlate with axon function as measured with in vivo electrophysiology? (3) Do the in vivo DTI biomarkers accurately correlate with neurological disabilities in human cervical spondylotic myelopathy (CSM) patients? These questions will be addressed by performing the mechanistic assessment of the in vivo DTI derived biomarker of axonal injury and its application as the outcome predictor of SCI using YFP and shiverer-YFP mice (Aim 1), functional correlation of in vivo DTI biomarker of axonal injury with electrophysiology (Aim 2), and the human translation of this biomarker to CSM patients (Aim 3).
描述(由申请人提供):扩散张量成像(DTI)测量水分子的扩散,其反映了感兴趣组织的微观结构组织。以前,我们已经证明,水的扩散平行于纤维,轴向扩散,是远远大于垂直于纤维,径向扩散。我们进一步证明了脱髓鞘导致径向扩散率增加,轴突损伤导致白色损伤小鼠模型轴向扩散率降低。在这个提议中,我们假设轴突损伤的体内DTI生物标志物,即,降低轴向扩散率,可作为脊髓损伤(SCI)预后预测的早期和准确的替代终点。脊髓损伤后急性期发生的轴索损伤是导致脊髓损伤后长期神经功能障碍的主要原因。因此,拟议研究的主要目标是确定在什么损伤后的时间点可以使用DTI准确预测功能(行为和电生理)的SCI啮齿动物模型的结果。还将对脊髓型颈椎病(CSM)患者轴索损伤的DTI生物标志物的使用进行翻译,以测试该标志物在临床环境中的疗效。提出了三个关键问题:(1)体内DTI轴突损伤生物标志物是否反映了SCI小鼠的潜在结构变化并预测了长期神经学结果?(2)体内DTI生物标志物与轴突功能相关吗?(3)在脊髓型颈椎病(CSM)患者中,体内DTI生物标记物与神经功能障碍准确相关吗?这些问题将通过使用YFP和shiverer-YFP小鼠(目标1)进行轴突损伤的体内DTI衍生生物标志物的机制评估及其作为SCI结果预测因子的应用,轴突损伤的体内DTI生物标志物与电生理学的功能相关性(目标2)以及该生物标志物对CSM患者的人类翻译(目标3)来解决。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHENG-KWEI SONG其他文献

SHENG-KWEI SONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHENG-KWEI SONG', 18)}}的其他基金

Virtual Histology for Assessing MS Pathologies
用于评估多发性硬化症病理学的虚拟组织学
  • 批准号:
    10517501
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Virtual Histology for Assessing MS Pathologies
用于评估多发性硬化症病理学的虚拟组织学
  • 批准号:
    10308715
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
IMAGING OPTIC NERVE FUNCTION AND PATHOLOGY
视神经功能和病理学成像
  • 批准号:
    8912809
  • 财政年份:
    2015
  • 资助金额:
    $ 39.63万
  • 项目类别:
Image Data Acquisition, Analysis, and Modeling Core
图像数据采集、分析和建模核心
  • 批准号:
    9275044
  • 财政年份:
    2008
  • 资助金额:
    $ 39.63万
  • 项目类别:
Validating diffusion MRI biomarkers of inflammation and axon pathologies in EAE
验证 EAE 中炎症和轴突病理的扩散 MRI 生物标志物
  • 批准号:
    8826186
  • 财政年份:
    2008
  • 资助金额:
    $ 39.63万
  • 项目类别:
Image Data Acquisition, Analysis, and Modeling Core
图像数据采集、分析和建模核心
  • 批准号:
    8741889
  • 财政年份:
    2008
  • 资助金额:
    $ 39.63万
  • 项目类别:
Image Data Acquisition, Analysis, and Modeling Core
图像数据采集、分析和建模核心
  • 批准号:
    9085409
  • 财政年份:
    2008
  • 资助金额:
    $ 39.63万
  • 项目类别:
Validating diffusion MRI biomarkers of inflammation and axon pathologies in EAE
验证 EAE 中炎症和轴突病理的扩散 MRI 生物标志物
  • 批准号:
    8741884
  • 财政年份:
    2008
  • 资助金额:
    $ 39.63万
  • 项目类别:
Noninvasive Quantification of Axon Damage in EAE and MS
EAE 和 MS 中轴突损伤的无创定量
  • 批准号:
    7276107
  • 财政年份:
    2006
  • 资助金额:
    $ 39.63万
  • 项目类别:
Noninvasive Quantification of Axon Damage in EAE and MS
EAE 和 MS 中轴突损伤的无创定量
  • 批准号:
    7360314
  • 财政年份:
    2006
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了